Definitions
Sorry, no definitions found. Check out and contribute to the discussion of this word!
Etymologies
Sorry, no etymologies found.
Support
Help support Wordnik (and make this page ad-free) by adopting the word tiuxetan.
Examples
-
The new drugs include rituximab (sold as Rituxan), with four boxed warnings, and ibritumomab tiuxetan (Zevalin), with two boxed warnings, among others.
-
The new drugs include rituximab (sold as Rituxan), with four boxed warnings, and ibritumomab tiuxetan (Zevalin), with two boxed warnings, among others.
-
ZEVALIN (ibritumomab tiuxetan) is indicated for the treatment of patients with previously untreated follicular non-Hodgkin's Lymphoma (NHL), who achieve a partial or complete response to first-line chemotherapy.
-
ZEVALIN (ibritumomab tiuxetan) is indicated for the treatment of patients with previously untreated follicular non-Hodgkin's Lymphoma (NHL), who achieve a partial or complete response to first-line chemotherapy.
-
The new drugs include rituximab (sold as Rituxan), with four boxed warnings, and ibritumomab tiuxetan (Zevalin), with two boxed warnings, among others.
-
The new drugs include rituximab (sold as Rituxan), with four boxed warnings, and ibritumomab tiuxetan (Zevalin), with two boxed warnings, among others.
-
The new drugs include rituximab (sold as Rituxan), with four boxed warnings, and ibritumomab tiuxetan (Zevalin), with two boxed warnings, among others.
-
ZEVALIN (ibritumomab tiuxetan) is a CD20-directed radiotherapeutic antibody administered as part of the ZEVALIN therapeutic regimen.
-
-- (BUSINESS WIRE) -- Spectrum Pharmaceuticals (NasdaqGM: SPPI), a commercial-stage biotechnology company with a focus in oncology, today announced ZEVALIN® (ibritumomab tiuxetan), a CD20-directed radiotherapeutic antibody, received approval from the U.S.
-
Data from clinical trials suggest that radio-immunotherapy (RIT) consolidation therapy is an important treatment approach for patients with follicular lympho ma (FL), with striking phase 3 results recently published for 90Y-ibritumomab tiuxetan
Comments
Log in or sign up to get involved in the conversation. It's quick and easy.